Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

New article series

Hypoglycemia in people taking alpha-glucosidase inhibitors

Sanjay Kalra

Hypoglycemia presentations that require deviation from standard management are rare, but challenging. To learn how to proceed in such cases, follow the latest series by Sanjay Kalra, outlining these instances and offering pragmatic advice.

Ask the expert

DKD treatment update: SGLT2 inhibitors and finerenone

Ask the expert Amirt Lamba, Ian de Boer

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

ESC 2021 Congress news

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Heart pills

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

New additions to the Adis Journal Club

Drugs Journal

Browse September's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Hypoglycemia

21-09-2021 | Hypoglycemia | View from the clinic | Article

Hypoglycemia in people taking alpha-glucosidase inhibitors

Sanjay Kalra explains how use of alpha-glucosidase inhibitors in people with type 2 diabetes can complicate the treatment of hypoglycemia.

IN FOCUS | Chronic kidney disease

15-09-2021 | ESC 2021 | Conference coverage | Video

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.

IN FOCUS | SGLT2 inhibitors

07-09-2021 | Nephropathy | Ask the expert | Article

DKD treatment update: SGLT2 inhibitors and finerenone

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

IN FOCUS | Cardiovascular disorders

20-09-2021 | Heart failure | News

Gestational diabetes may flag early HF risk

The presence of gestational diabetes mellitus may identify women at an increased risk for experiencing hospitalization for heart failure within the next few years, research suggests.

ESC Congress 2021 coverage

27 – 30 August: Browse all of the latest coverage


IN FOCUS | GLP-1 receptor agonists

29-06-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-O: Efpeglenatide offers cardiorenal protection in type 2 diabetes

Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.

IN FOCUS | Mental health & psychosocial care

21-07-2021 | Disordered eating | News

Eating disorders tied to increased DKA, mortality risk in young people with type 1 diabetes

The presence of an eating disorder diagnosis significantly increases the risk for diabetic ketoacidosis and all-cause mortality in adolescents and young adults with type 1 diabetes, shows a population-based study.

Addressing suicide risk in diabetes

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

IN FOCUS | Metformin & oral combination therapies

15-07-2021 | Glycemic control | News

Early second-line therapy response predicts sustained HbA1c reductions in type 2 diabetes

Early achievement of a glycated hemoglobin (HbA1c) level below 7% is a key factor in maintaining long-term glucose control in people with type 2 diabetes initiating second-line glucose-lowering therapy, DISCOVER study data show.

IN FOCUS | Tirzerpatide

26-06-2021 | ADA 2021 | Conference coverage | News

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

IN FOCUS | Diabetes devices & technology

02-06-2021 | ATTD 2021 | Conference coverage | News

Studies support wider CGM access in type 2 diabetes

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

IN FOCUS | Obesity & lifestyle interventions

15-07-2021 | Epidemiology | News

Global variation in optimal BMI, age cutoffs for diabetes screening

Researchers find large geographic differences in the influence of BMI and age on the risk for type 2 diabetes in low- and middle-income countries.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

Podcasts

Interviews with experts on diabetes patient care

Image Credits